Evidence map›Paper›PMID 41614247›Full record

ArticleHypertension (Dallas, Tex. : 1979)2026

Galectin-1 Is a Marker but Not a Mediator of Heart Failure With Preserved Ejection Fraction.

Jean W Wassenaar, C Duncan Smart, Daniel J Fehrenbach, Megan M Shuey, Pranoy Sangowdar, Lin Zhong, Francis J Miller, Quinn S Wells, Shi Huang, Sean P Collins and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hypertension (Dallas, Tex. : 1979), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jean W WassenaarDepartment of Medicine (J.W.W., M.M.S., L.Z., F.J.M., Q.S.W., D.K.G., A.C.D.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-2835-6338
C Duncan SmartDepartment of Medicine, University of Minnesota, Minneapolis (C.D.S.).ORCID 0000-0003-0391-3916
Daniel J FehrenbachDepartment of Medicine, Indiana University School of Medicine, Indianapolis (D.J.F., M.S.M.).ORCID 0000-0003-3382-464X
Megan M ShueyDepartment of Medicine (J.W.W., M.M.S., L.Z., F.J.M., Q.S.W., D.K.G., A.C.D.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0003-2866-3562
Pranoy SangowdarDepartment of Biological Sciences (P.S.), Vanderbilt University, Nashville, TN.ORCID 0009-0000-8752-0321
Lin ZhongDepartment of Medicine (J.W.W., M.M.S., L.Z., F.J.M., Q.S.W., D.K.G., A.C.D.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0003-2550-3758
Francis J MillerDepartment of Medicine (J.W.W., M.M.S., L.Z., F.J.M., Q.S.W., D.K.G., A.C.D.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0001-5822-0549
Quinn S WellsDepartment of Medicine (J.W.W., M.M.S., L.Z., F.J.M., Q.S.W., D.K.G., A.C.D.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0003-3899-0313
Shi HuangDepartment of Biostatistics (S.H.), Vanderbilt University Medical Center, Nashville, TN.
Sean P CollinsDepartment of Emergency Medicine (S.P.C., A.B.S., K.F.M.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-2305-9836
Alan B StorrowDepartment of Emergency Medicine (S.P.C., A.B.S., K.F.M.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-2893-808X
Karen F MillerDepartment of Emergency Medicine (S.P.C., A.B.S., K.F.M.), Vanderbilt University Medical Center, Nashville, TN.
Deepak K GuptaDepartment of Medicine (J.W.W., M.M.S., L.Z., F.J.M., Q.S.W., D.K.G., A.C.D.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0003-2191-3485
Amanda C DoranDepartment of Medicine (J.W.W., M.M.S., L.Z., F.J.M., Q.S.W., D.K.G., A.C.D.), Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-1576-6274
Meena S MadhurDepartment of Medicine, Indiana University School of Medicine, Indianapolis (D.J.F., M.S.M.).ORCID 0000-0002-0407-634X

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · VANDERBILT UNIVERSITY MEDICAL CENTER · 1995 to 2025
$32.7M
CLINICAL PHARMACOLOGY TRAINING PROGRAMT32GM007569 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · 1985 to 2025
$3.0M
Building Interdisciplinary Research Careers in Women's *K12HD043483 · VANDERBILT UNIVERSITY · 2002 to 2005
$1.9M
Hypertension-associated Trained Immunity in Myeloid Cells is a Determinant of AtherosclerosisR01HL174961 · VANDERBILT UNIVERSITY MEDICAL CENTER · 2025 to 2025
$786k
Critical Mediators of Inflammation Resolution and Immune Memory in AtherosclerosisR01HL159487 · VANDERBILT UNIVERSITY MEDICAL CENTER · 2025 to 2025
$581k
Immune Modulation in HypertensionR01HL161212 · INDIANA UNIVERSITY INDIANAPOLIS · 2025 to 2025
$566k
Novel role of ROCK2 in Immune Mechanisms of Takotsubo CardiomyopathyK99HL177309 · INDIANA UNIVERSITY INDIANAPOLIS · 2025 to 2025
$124k
American Heart Association-American Stroke Association 24CDA1278132NCATS NIH HHS UL1 TR000445NCI NIH HHS P30 CA068485NCRR NIH HHS S10 RR025141NHLBI NIH HHS F30 HL151069NHLBI NIH HHS K99 HL177309NHLBI NIH HHS R01 HL133860NHLBI NIH HHS R01 HL153607NHLBI NIH HHS R01 HL159487NHLBI NIH HHS R01 HL161212NHLBI NIH HHS R01 HL174961NICHD NIH HHS K12 HD043483NIGMS NIH HHS T32 GM007569NIH HHS S10 OD023475
6 · The paper itself

Abstract

backgroundThe immune system is emerging as a key player in driving cardiac remodeling in heart failure with preserved ejection fraction (HFpEF). Galectin-1 (

methodsGalectin-1 was measured using the Olink proximity extension assay in human cohorts. HFpEF was induced in mice with myeloid-specific and global deletion of galectin-1 and corresponding controls using the hypertensive deoxycorticosterone acetate-salt model.

resultsPlasma galectin-1 was higher in both a preclinical model of HFpEF (

conclusionsGreater circulating galectin-1 levels are associated with a higher risk of incident heart failure and higher NT-proBNP among patients with acute HFpEF. However, neither global nor myeloid deficiency of galectin-1 altered the cardiovascular phenotype in a preclinical model of HFpEF, suggesting that it is a marker but not a causal mediator of the disease.

Indexed as

Galectin 1Heart FailureStroke VolumeAgedAnimalsBiomarkersDisease Models, AnimalFemaleHumansMaleMiceNatriuretic Peptide, BrainPeptide FragmentsBiomarkersGalectin 1Natriuretic Peptide, BrainPeptide Fragmentsgalectin-1heart failureinflammationmacrophages

Identifiers

PMID41614247
PMCPMC12879785

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.